Overview
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Completed
Trial end date:
2014-12-01
2014-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Tris Pharma, Inc.Treatments:
AmphetamineCriteria
Inclusion Criteria:- Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this
condition
Exclusion Criteria:
- Other serious illnesses or conditions that would put the patient at particular risk
for safety events or would interfere with treatment/assessment of ADHD